Financial Performance - Revenue increased significantly to RMB 82.5 million for the six months ended June 30, 2023, compared to RMB 37.4 million for the same period in 2022, representing a growth of 120.5%[22] - The company recorded a net loss of RMB 41.0 million for the six months ended June 30, 2023, a substantial narrowing of 58.9% compared to a net loss of RMB 99.7 million for the same period in 2022[11] - Total revenue increased by 120.6% from RMB 37.4 million for the six months ended June 30, 2022, to RMB 82.5 million for the six months ended June 30, 2023[89] - The company reported a total comprehensive loss of RMB 42,217,000 for the six months ended June 30, 2023, compared to RMB 99,760,000 for the same period in 2022, showing a reduction of approximately 58%[168] - The company reported a net loss attributable to ordinary equity holders of RMB 36,970,000 for the six months ended June 30, 2023, compared to a loss of RMB 99,684,000 for the same period in 2022, indicating a reduction in losses[193] Revenue Sources - Revenue from the Eagle Eye Medical segment rose by 137.3% to RMB 29.8 million, while Eagle Eye Health revenue increased by 26.0% to RMB 21.7 million, and Eagle Eye Vision Health revenue surged by 307% to RMB 31.0 million[25] - Revenue from AI software and hardware integrated solutions for medical institutions (Eagle Eye Medical) reached RMB 29,845,000, up from RMB 12,577,000, representing an increase of 137.5%[181] - Revenue from customer contracts for the six months ended June 30, 2023, was RMB 82,502,000, a significant increase of 120.5% compared to RMB 37,407,000 for the same period in 2022[181] Expenses and Costs - Research and development expenses decreased by 18.8% from RMB 69.6 million for the six months ended June 30, 2022, to RMB 56.5 million for the six months ended June 30, 2023, mainly due to a reduction in employee benefits expenses[4] - Administrative expenses increased by 28.0% from RMB 31.7 million for the six months ended June 30, 2022, to RMB 40.6 million for the same period in 2023, mainly due to the adoption of a new employee equity incentive plan[9] - The sales cost increased by 103.0% from RMB 15.3 million for the six months ended June 30, 2022, to RMB 31.1 million for the six months ended June 30, 2023[78] - The group's cost of sold inventory increased to RMB 18,801 thousand for the six months ended June 30, 2023, compared to RMB 4,456 thousand for the same period in 2022, representing a significant rise[199] Assets and Liabilities - Cash and cash equivalents decreased from RMB 1,268.3 million as of December 31, 2022, to RMB 876.4 million as of June 30, 2023, primarily due to cash outflows for purchasing financial assets and equity investments[16] - Current assets amounted to RMB 1,408.8 million as of June 30, 2023, with cash and cash equivalents at RMB 876.4 million[125] - Total liabilities increased to RMB 90,262,000 as of June 30, 2023, compared to RMB 64,665,000 as of December 31, 2022, marking an increase of approximately 39%[170] - The company's net assets as of June 30, 2023, were RMB 1,665,049,000, slightly down from RMB 1,671,362,000 as of December 31, 2022, indicating a decrease of about 0.4%[172] Product Development and Innovation - The company launched a new myopia treatment product that received the highest award at the Geneva International Invention Exhibition[27] - The AI-FUNDUSCAMERA-P and myopia treatment products received special recognition at the Geneva International Invention Exhibition in April 2023[32] - The company plans to submit applications for regulatory approval for new products, including the AI-FUNDUSCAMERA-M in Q4 2023 and myopia treatment products in Q4 2024[39] - The company is developing five additional SaMD products for early detection and diagnosis of various health conditions based on its AI retinal imaging technology[150] Market Expansion and Strategy - The company aims to expand its sales channels and expects sales growth in new markets such as Malaysia, Singapore, Thailand, UAE, and South Africa in 2023[75] - The number of service points covered by the Eagle Eye Health strategy increased by over 34.7% year-on-year, reaching 1,371 locations[74] - The number of service points using the company's SaMD and health risk assessment solutions increased from 2,681 to 3,331 year-on-year[80] Acquisitions and Investments - The company acquired 70% of Beijing Zhihong Technology Co., Ltd. for RMB 182 million on May 19, 2023, focusing on ophthalmic medical devices and software as a medical device (SaMD) development[117] - The fair value of identifiable assets and liabilities at the acquisition date was RMB 78.044 million, with goodwill recognized at RMB 127.368 million[163] Employee and Operational Insights - The total employee compensation cost for the six months ended June 30, 2023, was RMB 98.1 million, with 369 full-time employees as of the same date[140] - The internal sales and marketing team has grown to 103 members, providing customized support throughout the customer lifecycle[80] - The company has implemented a 2022 H-share equity incentive plan to motivate its employees[140] Regulatory and Compliance - The company is recognized as a high-tech enterprise and benefits from a preferential income tax rate of 15%[188] - The company did not declare or pay any dividends for the six months ended June 30, 2023, consistent with the previous year[190] Other Financial Metrics - Other income and gains increased from RMB 28.6 million for the six months ended June 30, 2022, to RMB 49.8 million for the six months ended June 30, 2023, primarily due to improved returns on fund management[1] - The average charge per test for the company's services rose to RMB 20.87, an increase of 8.1% compared to RMB 19.3 in the same period of 2022[80]

Financial Performance - Revenue for 2022 was 113,657 thousand RMB, a decrease of 1.3% compared to 115,181 thousand RMB in 2021[1] - Operating loss for 2022 was 182,301 thousand RMB, an increase of 28.2% compared to 142,229 thousand RMB in 2021[1] - Gross profit decreased from RMB 70.2 million in 2021 to RMB 55.9 million in 2022, with overall gross margin dropping from 61.0% to 49.1%, while AI software solutions maintained a 64.0% gross margin[28] - R&D expenses increased by 95.4% from RMB 64.3 million in 2021 to RMB 125.6 million in 2022, driven by team expansion and investments in AI software solutions and hardware products[31] - Sales expenses rose by 37.8% from RMB 72.6 million in 2021 to RMB 100.0 million in 2022, primarily due to the expansion of the sales and marketing team[32] - The company recorded a loss of RMB 182.7 million in 2022, compared to a loss of RMB 142.5 million in 2021[35] - Pre-tax loss for the year ending December 31 was RMB 182,740 thousand, compared to RMB 142,527 thousand in the previous year[174] - Gross profit for 2022 was RMB 55.852 million, compared to RMB 70.241 million in 2021, RMB 29.087 million in 2020, and RMB 16.107 million in 2019[192] Assets and Liabilities - Non-current assets increased to 64,137 thousand RMB in 2022, up 32.1% from 48,566 thousand RMB in 2021[2] - Current assets decreased to 1,675,818 thousand RMB in 2022, down 9.2% from 1,845,611 thousand RMB in 2021[2] - Inventory increased from RMB 7.7 million in 2021 to RMB 29.6 million in 2022, mainly due to the procurement of raw materials for the production of self-developed fundus cameras[37] - Cash and cash equivalents decreased from RMB 1,784.6 million in 2021 to RMB 1,268.3 million in 2022, due to investments in financial assets, industrial funds, and operational expenses[39] - Accounts receivable increased from RMB 34.0 million in 2021 to RMB 63.9 million in 2022, with the average turnover days rising from 87 days to 169 days[62] - Contract liabilities increased from RMB 17.1 million in 2021 to RMB 18.2 million in 2022, driven by prepayments from new customer contracts in the second half of 2022[66] - Property, plant, and equipment decreased from RMB 45.0 million as of December 31, 2021, to RMB 33.1 million as of December 31, 2022, primarily due to increased depreciation of hardware equipment[88] - The company is in a net cash position as of December 31, 2022, making the debt-to-asset ratio not applicable[70] - The company has no bank loans or other borrowings as of December 31, 2022 (2021: none)[93] AI and Medical Device Development - The company's AI-based retinal imaging diagnostic product, Airdoc-AIFUNDUS (1.0), is the first AI retinal imaging recognition product to receive a Class III medical device certificate from the National Medical Products Administration[3] - Airdoc-AIFUNDUS (2.0) is expected to submit an application for Class III medical device certification for hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration in Q4 2022[9] - The company's AI diagnostic system (RAIDS) demonstrated a sensitivity of 89.8% in detecting 10 types of retinal diseases, with accuracy ranging from 95.3% to 99.9%[5] - The company's AI-FUNDUSCAMERA-P, a Class II medical device, was approved in March 2021[8] - Airdoc-AIFUNDUS (2.0) completed clinical trials in Q3 2022 and applied for new indications approval in Q4 2022, aiming to become China's first AI-assisted diagnostic SaMD with multiple approved indications[13] - RAIDS demonstrated 89.8% sensitivity in detecting 10 retinal diseases and accuracy ranging from 95.3% to 99.9% in distinguishing them, outperforming human retinal experts[18] - The AI-FUNDUSCAMERA-D, a fully automated desktop fundus camera, received Class II medical device registration from the Shanghai Medical Products Administration in July 2022[42] - The company has developed over 90 deep learning algorithms to cover a wide range of diseases, lesions, and health risks[43] - Airdoc-AIFUNDUS (2.0) expanded its indications to include hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration (AMD), with clinical trials completed in Q3 2022 and registration certificate updates applied for in Q4 2022[177] - AI-FUNDUSCAMERA-D, a fully automated desktop fundus camera, received Class II medical device registration from the Shanghai Medical Products Administration in July 2022, offering high-quality imaging at a lower cost compared to traditional high-end models[178] - The company developed AI-based retinal imaging solutions for early detection, diagnosis, and health risk assessment, covering a wide range of diseases and lesions[197] Health Risk Assessment Solutions - The company completed over 4.3 million tests in 2022 using its SaMD and health risk assessment solutions[8] - The company's health risk assessment solutions cover a wide range of conditions, including retinal abnormalities, cardiovascular abnormalities, and anemia[11] - The company's health risk assessment solutions cover 55 types of lesions and diseases, with plans to expand coverage to include conditions like hyperthyroidism, Graves' eye disease, and dementia[15] - The company's health risk assessment solutions can be sold in health and eye health management scenarios without requiring regulatory approval or registration[199] Customer and Market Expansion - Customer base grew from 244 in 2021 to 397 in 2022, with 2,371 service outlets using SaMD and health risk assessment solutions monthly, despite a 12% YoY decrease in total tests to 4.3 million[20] - The company's solutions served nearly 94 insurance companies, including top commercial insurers, and were used in over 780 pharmacies, with monthly service outlets increasing by over 200% YoY[23] - Revenue from Eagle Health reached RMB 41.8 million during the reporting period[23] - The company achieved solid progress in commercializing its three business pillars: Eagle Eye Medical, Eagle Eye Health, and Eagle Eye Eye Health, with AI-based SaMD, health risk assessment solutions, and hardware devices widely adopted across various health service scenarios[179] - The company established its own factory in Changsha, Hunan, enabling self-controlled production capabilities, and launched a myopia treatment product to diversify its product portfolio[179] Corporate Governance and Leadership - The Board continues to review and oversee operations to maintain high corporate governance standards[83] - The company's board consists of 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors[119] - The company has entered into three-year service agreements with directors Chen Xin, Luo Ting, Wang Lin, and Zhu Tingyao, effective from their respective appointment dates[123] - The company provides professional development training for directors, with costs covered by the company and annual submission of signed training records required[116] - The company has arranged appropriate insurance coverage for directors and senior officers against potential legal liabilities arising from corporate activities, with annual review of coverage[127] - The company ensures compliance with listing rules by maintaining at least three independent non-executive directors, one of whom must have appropriate professional qualifications or accounting/financial management expertise[106] - The company has received annual written confirmations from independent non-executive directors regarding their independence in accordance with listing rules[121] - The company has established four board committees: Audit Committee, Remuneration and Appraisal Committee, Nomination Committee, and Strategy Committee[125] - The company provides updates on listing rules and regulatory developments to directors to ensure compliance with good corporate governance practices[129] - The company's board is responsible for leading and monitoring the company's affairs, providing strategic guidance, and overseeing operational and financial performance[113] - The company's directors are required to participate in continuous professional development to maintain and update their knowledge and skills[114] - Zhang Dalei, aged 40, was appointed as CEO on September 9, 2015, and currently serves as both Chairman and CEO, leveraging his extensive experience in the medical device industry[141] - Yang Wenting, aged 37, joined the company in June 2020 and was appointed as CFO on December 25, 2020, with a background in finance and investment management[133] - The company's board consists of four executive directors, two non-executive directors, and three independent non-executive directors, ensuring a balanced and independent governance structure[141] - The company has adopted the Corporate Governance Code as outlined in Appendix 14 of the Listing Rules to regulate its corporate governance practices[139] - All directors and supervisors confirmed compliance with the standard code regarding securities trading during the reporting period[142] - Newly appointed directors receive necessary onboarding training and information to ensure they understand the company's operations and their legal responsibilities[143] - Wu Gangping, aged 65, was appointed as an independent non-executive director on April 30, 2021, bringing over 30 years of professional experience in the accounting industry[147] - Dr. Wu Yangfeng, aged 60, was appointed as an independent non-executive director on December 25, 2020, with a background in clinical research and epidemiology[148] - The company emphasizes the importance of separating the roles of Chairman and CEO, although currently, both roles are held by Zhang Dalei due to his strategic importance to the company[141] - The company ensures that its senior management and directors are well-informed about legal and regulatory updates relevant to their roles[143] Research and Development - The company collaborated on a study published in Age and Ageing (IF:12.782), the first global research combining AI technology with fundus imaging to identify high-risk dementia populations[19] - The company has developed over 90 deep learning algorithms to cover a wide range of diseases, lesions, and health risks[43] Inventory and Sales Management - Inventory management is closely monitored to maintain optimal levels aligned with near-term usage expectations[89] - Sales cost increased by 28.6% from RMB 44.9 million in 2021 to RMB 57.8 million in 2022, mainly due to higher procurement costs for myopia treatment devices[53] - Sales cost for the year ending December 31 was RMB 57,805 thousand, a decrease from RMB 44,940 thousand in the previous year[174] Treasury and Financial Management - The company adopts a prudent treasury policy to ensure liquidity structure meets funding needs[71] - The company's H-shares were listed on the Main Board of the Hong Kong Stock Exchange on November 5, 2021, under Chapter 18A of the Listing Rules[175] Leadership and Expertise - Zhang Dalei, the founder, has over 13 years of experience in managing high-tech companies and specializes in AI technology R&D[97] - Dr. Chen Yuzhong, responsible for medical R&D and product registration, has over 21 years of experience in applying IT to clinical practice[74] - Chen Hailong, responsible for product structure design and R&D, has over 16 years of experience in the IT industry[101] - Wang Lin, appointed as an executive director in March 2023, has over 12 years of legal practice experience[102]

截至2022年12月31日，我們概無任何重大資本承擔（2021年12月31日：無）。 截至2022年12月31日，我們質押了一筆金額為人民幣150.0百萬元的存款於保證金賬戶， 以擔保一筆潛在的貸款，但並未進一步實現，因此該質押在報告期後被解除（2021年12月 31日：無）。除此之外，我們並無質押任何資產。 截至2022年12月31日，本公司有297名僱員。截至2022年12月31日止年度，本集團產生的 總薪酬成本（包括股份支付）為人民幣216.0百萬元（2021年：人民幣129.5百萬元）。 本公司股份於2021年11月5日在聯交所上市。經最終確定及結算上市開支（包括專業人士 完成工作所產生的相關開支）後，全球發售的最終所得款項淨額為1,550.7百萬港元。因 此，「未來計劃及所得款項用途」一節所披露所得款項淨額的計劃用途如下表所示按比例 調整。計劃用途及分配百分比保持不變。截至2022年12月31日，全球發售所得款項淨額 的約304.7百萬港元已作如下用途： 投資於產業基金 於2023年1月13日，董事會議決建議採納2022年股權激勵計劃。該計劃須待股東於本公司 將於2023年3月30日舉行的股東特別大 ...

Financial Performance - Revenue for the first half of 2022 was RMB 37,407,000, a decrease of 24.3% compared to RMB 49,477,000 in the same period of 2021[12]. - Gross profit for the first half of 2022 was RMB 22,071,000, down 30.5% from RMB 31,703,000 in the first half of 2021[12]. - Operating loss for the first half of 2022 was RMB 99,492,000, compared to RMB 37,052,000 in the same period of 2021, indicating a significant increase in losses[12]. - Basic and diluted loss per share for the first half of 2022 was RMB (0.98), compared to RMB (0.50) in the same period of 2021[12]. - The company recorded a loss of RMB 99,760,000 for the six months ended June 30, 2022, compared to a loss of RMB 37,448,000 in the same period last year[154]. - The net loss before tax for the six months ended June 30, 2022, was RMB 99,684,000, compared to a loss of RMB 37,597,000 for the same period in 2021, indicating an increase in losses[196]. - The company reported a significant increase in employee costs, which rose to RMB 85,441,000 for the six months ended June 30, 2022, compared to RMB 41,092,000 in the same period of 2021, reflecting a 108% increase[190]. Assets and Liabilities - Non-current assets as of June 30, 2022, were RMB 51,158,000, an increase from RMB 48,566,000 at the end of 2021[12]. - Current assets decreased to RMB 1,743,070,000 as of June 30, 2022, from RMB 1,845,611,000 at the end of 2021[12]. - The company's cash and cash equivalents stood at RMB 1,421,281,000, down from RMB 1,784,648,000 at the end of 2021[156]. - Accounts receivable rose to RMB 43.7 million as of June 30, 2022, compared to RMB 34.0 million as of December 31, 2021, primarily due to slower payment collection from customers affected by the pandemic[82]. - Cash and cash equivalents decreased by RMB 370,186,000 during the first half of 2022, compared to an increase of RMB 200,753,000 in the same period of 2021[173]. - The company's current assets amounted to RMB 1,743.1 million as of June 30, 2022, with current liabilities of RMB 50.8 million, indicating a strong liquidity position[86]. Research and Development - R&D expenses for the six months ended June 30, 2022, amounted to RMB 69.6 million, a significant increase from RMB 24.0 million for the same period in 2021, primarily due to the expansion of the R&D team and investments in AI software solutions and hardware[72]. - The company has developed over 90 deep learning algorithms to enhance early detection and diagnosis of chronic diseases[40]. - The company is focused on integrating AI software and hardware solutions to enhance early detection and diagnosis of chronic diseases[16]. - The company plans to continue focusing on the development of AI retinal imaging recognition solutions and expanding its market presence in the healthcare sector[175]. Product Development and Market Strategy - The company has developed solutions for 55 types of lesions and diseases, including conditions like hyperthyroidism and dementia[15]. - The Airdoc-AIFUNDUS (1.0) achieved an industry-leading sensitivity of 91.75% and specificity of 93.10% in a clinical trial involving 1,000 patients[27]. - Airdoc-AIFUNDUS (2.0) is currently in the late-stage clinical trial phase, with plans to submit for regulatory approval in Q4 2022[28]. - The company has developed a comprehensive AI-based solution for early detection and diagnosis of chronic diseases, including various SaMD products[26]. - The company aims to penetrate various health service scenarios through a multi-channel sales and marketing strategy[16]. - The company is developing five additional SaMDs for early detection and diagnosis of various retinal diseases, including ICVD and ASCVD[33]. Sales and Marketing - The company has established its own production facilities and is prepared to produce hardware equipment internally since the second half of 2022[45]. - The internal sales and marketing team consists of 161 members, providing customized support throughout the product lifecycle[50]. - The company is actively assisting hospitals in multiple provinces to obtain pricing guidelines for Airdoc-AIFUNDUS, despite challenges posed by COVID-19[53]. - The company has developed a flexible, multi-channel sales and marketing strategy to cover various commercialization channels in healthcare and health management[49]. - The company aims to enhance penetration in hospitals and expand coverage to primary healthcare institutions, as most medical facilities in China are primary care[54]. Customer and Market Growth - The number of customers increased from 83 to 265 year-on-year, representing a growth of 219.3%[49]. - The total number of tests conducted during the reporting period was 1,632,753, a decrease of 34.8% compared to the previous year due to pandemic-related restrictions[49]. - Revenue from Airdoc Medical reached RMB 12.6 million during the reporting period, with RMB 9.5 million generated from sales of Airdoc-AIFUNDUS (1.0)[54]. - Revenue from the Eagle Eye Medical segment was RMB 12.6 million, up from RMB 10.3 million in the previous year, representing a growth of 21.9%[64]. - Revenue from the Eagle Eye Health segment was RMB 17.2 million, down 40.0% from RMB 28.7 million in the previous year[64]. Regulatory and Compliance - The AI-FUNDUSCAMERA-P and AI-FUNDUSCAMERA-D received regulatory approval in March 2021 and July 2022, respectively[18]. - The AI-FUNDUSCAMERA-M integrates multiple biosensors to capture retinal images and other physiological data, with regulatory approval expected in Q4 2023[39]. - The company’s health risk assessment solutions can evaluate risks for various conditions without needing regulatory approval[23]. Shareholder Information - As of June 30, 2022, Mr. Zhang, the CEO, holds 17,248,854 shares of domestic stock, representing 22.22% of the total issued shares[96]. - The total number of shares held by major shareholder Chen is 1,912,760 domestic shares, which is 2.46% of the total[102]. - The company has a total of 24,492,922 shares held under a concert party agreement, indicating strategic voting alignment among key shareholders[97]. - The percentage of shares held by UBS Group AG is 6.06%, reflecting its significant stake in the company[105]. Miscellaneous - The company does not recommend an interim dividend for the six months ended June 30, 2022[133]. - There were no significant legal disputes or arbitration matters as of June 30, 2022[138]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ended June 30, 2022[134].

Financial Performance - The company's revenue for 2021 was RMB 115,181 thousand, a significant increase from RMB 47,672 thousand in 2020, representing a growth of approximately 141%[10] - The gross profit for 2021 was RMB 70,241 thousand, compared to RMB 29,087 thousand in 2020, indicating a gross margin improvement[10] - The operating loss for 2021 was RMB 142,229 thousand, worsening from a loss of RMB 51,913 thousand in 2020[10] - The pre-tax loss for 2021 was RMB 142,527 thousand, compared to RMB 79,251 thousand in 2020, reflecting increased operational challenges[10] - The company reported a basic and diluted loss per share of RMB 1.76 for 2021, compared to RMB 1.36 in 2020, reflecting ongoing financial pressures[10] - Revenue increased by 141.6% from RMB 47.7 million for the year ended December 31, 2020, to RMB 115.2 million for the year ended December 31, 2021, primarily due to sales of SaMD and health risk assessment solutions[69] - Gross profit increased from RMB 29.1 million for the year ended December 31, 2020, to RMB 70.2 million for the year ended December 31, 2021, maintaining a gross margin of 61.0%[71] - The company recorded a loss of RMB 142.5 million for the year ended December 31, 2021, compared to a loss of RMB 79.6 million for the year ended December 31, 2020[86] Assets and Liabilities - The total assets as of December 31, 2021, were RMB 1,819,986 thousand, a substantial increase from RMB 408,450 thousand in 2020[10] - The non-current assets increased to RMB 48,566 thousand in 2021 from RMB 26,854 thousand in 2020, showing investment in long-term growth[10] - The current liabilities rose significantly to RMB 70,771 thousand in 2021 from RMB 24,898 thousand in 2020, indicating increased short-term financial obligations[10] - Cash and cash equivalents increased significantly from RMB 374.7 million as of December 31, 2020, to RMB 1,784.6 million as of December 31, 2021, mainly due to net proceeds from financing activities[94] - Trade receivables rose from RMB 19.5 million as of December 31, 2020, to RMB 34.0 million as of December 31, 2021, reflecting business growth and improved collection efforts[89] - Inventory increased from RMB 3.6 million as of December 31, 2020, to RMB 7.7 million as of December 31, 2021, due to purchases of third-party fundus cameras to meet business growth[88] - Trade and other payables increased from RMB 16.7 million as of December 31, 2020, to RMB 48.5 million as of December 31, 2021, driven by business expansion and accrued listing expenses[95] Research and Development - The internal R&D team consists of over 100 members, all holding at least a bachelor's degree, with expertise in various fields including deep learning and medical technology[50] - The company has developed over 80 deep learning algorithms for early detection, diagnosis, and health risk assessment solutions[46] - Research and development expenses rose by 51.9% from RMB 42.3 million in 2020 to RMB 64.3 million in 2021, primarily due to increased employee benefits and product registration costs[78] - The company plans to continuously develop and upgrade algorithms to address industry pain points, such as improving screening efficiency and diagnostic accuracy[50] Product Development and Market Expansion - The company aims to enhance its leading position in AI retinal imaging and accelerate commercialization across various healthcare scenarios[16] - The company has developed a comprehensive product portfolio that includes AI-based software and hardware solutions for early detection and diagnosis of chronic diseases[20] - The company plans to focus on expanding its market presence and developing new technologies in the upcoming fiscal year[14] - Airdoc-AlFUNDUS aims to capture significant market opportunities by ensuring compatibility with most existing fundus cameras[32] - The company plans to expand its health risk assessment indicators to include conditions like hyperthyroidism and dementia, responding to growing demand[40] - The company is focusing on market expansion strategies, including potential mergers and acquisitions to enhance its market presence[133] Corporate Governance - The company has established a strong governance structure with qualified individuals in key management positions[140] - The company has adopted the corporate governance code as per the listing rules, ensuring compliance since its listing date[149] - The board consists of four executive directors, two non-executive directors, and three independent non-executive directors[154] - The company has established service agreements with directors, each lasting three years, which can be terminated under specific terms[159] - Continuous professional development is encouraged for all directors, with necessary training provided for new appointees[163] - The company has a diversity policy in place for board composition, which is considered during the appointment and re-election of directors[159] Strategic Partnerships and Collaborations - The company is collaborating with over 40 insurance companies to provide health risk assessment solutions, including major firms like Ping An Insurance and China Pacific Insurance[61] - The company has expanded its commercial footprint into government projects, including establishing an intelligent eye health management platform in Beijing[65] - The company collaborates with government clients to manage chronic diseases in the elderly and eye health in children and adolescents[16] Management Team and Experience - The management team has a diverse background in technology, finance, and healthcare, positioning the company for future growth[119][120] - Dr. Chen has approximately 20 years of experience in applying information technology in clinical practice, including roles in major hospitals[112] - Mr. Chen has over 15 years of experience in the information technology industry, focusing on product structure design and R&D management[113] - The company’s chairman and CEO roles are held by the same individual, Mr. Zhang Dailai, who has extensive experience in the medical device software industry[150] Community and Shareholder Engagement - The company expressed gratitude to shareholders for their continued support, marking its first annual report as a listed entity[14] - The company is committed to long-term growth and creating shareholder value by adhering to its core values of inclusivity, professionalism, and long-termism[16]